Please login to the form below
ceftazidime
This page shows the latest ceftazidime news and features for those working in and with pharma, biotech and healthcare.
Allergan’s Avycaz breaks Gram-negative pneumonia antibiotic drought
Originally developed by Actavis (which was acquired by Allergan in a $25bn deal in 2014), Avycaz combines established cephalosporin antibiotic ceftazidime with avibactam, a novel beta lactamase inhibitor that helps tackle
Latest news
-
Pfizer launches new antibiotic Zavicefta in UK and Germany
The European Medicines Agency (EMA) cleared Zavicefta (ceftazidime and avibactam) for the treatment of complicated Gram-negative bacterial infections requiring hospitalisation last year.
-
AZ slims down again with sale of antibiotics to Pfizer
The deal includes the approved antibiotics Merrem (meropenem), Zinforo (ceftaroline fosamil) and just-licensed Zavicefta (ceftazidime/avibactam), as well as two injectable antibiotic candidates - Allergan-partnered ATM-AVI (aztreonam/avibactam) and
-
AZ gets EU green light for new antibiotic Zavicefta
The European Medicines Agency (EMA) cleared Zavicefta (ceftazidime and avibactam) for the treatment of serious Gram-negative bacterial infections requiring hospitalization.
-
Merck starts pivotal trials of new antibiotic combination
aeruginosa. AstraZeneca (AZ) recently secured CHMP backing in Europe for Zavicefta - which combines established cephalosporin antibiotic ceftazidime with new-generation beta lactamase inhibitor avibactam.
-
CHMP backs AZ's 'superbug' antibiotic product
The Committee for Medicinal Products for Human Use (CHMP) recommended approval of Zavicefta (ceftazidime/avibactam), which combines an established antibiotic with a new drug designed to overcome bacterial resistance. ... In the US, Actavis (now operating
More from news
Approximately 2 fully matching, plus 10 partially matching documents found.
Latest Intelligence
-
Deal Watch August 2016
14, 000. AstraZeneca (UK) antibiotic business. Pfizer (US). Asset acquisition. EU approved ceftazidime-avibactam), marketed meropenem and ceftaroline fosamil and clinical development assets aztreonam-avibactam (ATM-AVI) and CXL.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
-
Senior Medical Writer
-
Great salary and benefits
- Account Manager – Med Comms – London
-
Salary TBC
-
Senior Medical Writer
-
Great salary and bebefits
- FREELANCE Account Manager – Creative Healthcare Advertising – Lo...
-
SUPERB DAY RATES AVAILABLE
- Senior Medical Writer, Medical Communications, Relocate to Cardi...
-
Excellent Salary
- Senior Account Manager – Med Comms – Kent
-
Salary TBC
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
- Head of Operations/ BUD, Healthcare PR, London – Excellent leade...
-
Excellent Package
- Senior / Principal Regulatory Writer – Home Working - UK or US
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
-
Senior Programme Executive
-
Salary TBC
- Editor > Senior Editor – Medical Education – London
-
Very competitive with excellent benefits
-
Scientific Director
-
Great salary and bebefits
- Senior Account Manager / Account Director
-
Great salary and bebefits
- Principal Medical Writer, Medical Communications, Relocate to Ca...
-
Excellent Salary
- Editor – Medical Education Agency – Bucks
-
Salary TBC
- FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...
-
EXCELLENT DAY RATES AVAILABLE
-
Account Manager, Healthcare PR
-
£40, 000 – £42, 000 great benefits and bonuses
Subscribe to our email news alerts
PMHub
Anthill Agency
Anthill is a specialist digital agency and a strategic partner for life science companies....
Latest intelligence
- No incentive for a cure
- The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
- Why heading online for scientific meetings can yield greater HCP engagement
- Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
- The threat of antimicrobial resistance
- Why this issue is such a fundamental challenge...
Quick links
Infographics
